Non-Antibiotic Treatment for Equine Endometritis Study Data Published in International Peer-Reviewed Journal



    - data shows up to 70% efficacy using a controlled challenge model -

    BELLEVILLE, ON, April 3 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, today
announced that it has had an article published in the Journal of Equine
Veterinary Science outlining the effectiveness of its Mycobacterial Cell Wall
Extract (MCWE) in the treatment of endometritis in a challenge study with
susceptible mares. The Journal of Equine Veterinary Science is an
international publication designed for the practicing equine veterinarian,
equine researcher, and other equine health care specialist.
    Endometritis is a non-life threatening bacterial infection that affects
25% to 30% of broodmares worldwide. The disease results in low conception
rates or loss of pregnancies if conception occurs. If not successfully treated
during the acute phase (conventional treatment involves intrauterine or
intravenous antibiotics for three to four consecutive days), the original
infection can result in a chronic, degenerative inflammatory condition
compromising future fertility and requiring a laborious and costly battery of
treatments.
    The study outlined in the Journal of Equine Veterinary Science was
conducted by Dr. Dragan Rogan, Vice-President of Research & Development,
Bioniche Animal Health, with E. Fumoso, E. Rodriguez, J. Wade, and S.F.
Sanchez Bruni. After being inoculated with Streptococcus zooepidemicus, thirty
mares randomly received either the Bioniche MCWE (SettleTM) or placebo by both
intravenous and intrauterine modes of administration. Mares were examined at
ovulation and 7 days post-ovulation. Experimental bacterial infections
resulting in endometritis were observed in all placebo-treated mares, whereas
treatment with Settle resulted in the elimination of endometritis in 35% of
the mares by the time of ovulation and 70% of the mares by 7 days
post-ovulation.
    "Typically, mares with endometritis are treated with antibiotics," noted
Dr. Rogan. "There is a growing desire to minimize antibiotic use because of
concerns about microbial resistance. Settle offers a safe, effective, and
convenient stand-alone therapy for endometritis in mares. Both intrauterine
and intravenous routes of administration proved effective."

    About the Mycobacterial Cell Wall Technology Platform

    Bioniche's core mycobacterial cell wall technology platform comprises a
number of different compositions with a spectrum of activity that comprises
antiviral, antibacterial, immune stimulatory and immune adjuvant, as well as
anticancer and chemotherapeutic activity against cancer cells. A number of
formulations are commercialized for use in veterinary applications, including
Settle, which was approved by the U.S. Department of Agriculture (USDA) in
2004 for the treatment of equine endometritis caused by Streptococcus
zooepidemicus.

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
185 skilled personnel and has three operating business units: Human Health,
Animal Health, and Food Safety. The Company's primary goal is to develop
proprietary cancer therapies supported by revenues from marketed products in
human and animal health. For more information, please visit www.Bioniche.com.

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159EF




For further information:

For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058 ext. 1250, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com

Organization Profile

Telesta Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890